AR079164A1 - Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. - Google Patents

Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.

Info

Publication number
AR079164A1
AR079164A1 ARP100104362A ARP100104362A AR079164A1 AR 079164 A1 AR079164 A1 AR 079164A1 AR P100104362 A ARP100104362 A AR P100104362A AR P100104362 A ARP100104362 A AR P100104362A AR 079164 A1 AR079164 A1 AR 079164A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
alkoxy
alkyl
substituents selected
Prior art date
Application number
ARP100104362A
Other languages
English (en)
Spanish (es)
Inventor
Ritsuki Masuo
Teruhiko Inoue
Tetsudo Kaya
Koji Matsumura
Shinichi Kikuchi
Michihide Maekawa
Motoya Suzuki
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR079164A1 publication Critical patent/AR079164A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP100104362A 2009-11-25 2010-11-25 Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. AR079164A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25

Publications (1)

Publication Number Publication Date
AR079164A1 true AR079164A1 (es) 2011-12-28

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104362A AR079164A1 (es) 2009-11-25 2010-11-25 Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.

Country Status (31)

Country Link
US (6) US8299070B2 (cg-RX-API-DMAC7.html)
EP (3) EP2505586B1 (cg-RX-API-DMAC7.html)
JP (6) JP5734628B2 (cg-RX-API-DMAC7.html)
KR (1) KR101766502B1 (cg-RX-API-DMAC7.html)
CN (1) CN102712624B (cg-RX-API-DMAC7.html)
AR (1) AR079164A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010323579C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012012529B1 (cg-RX-API-DMAC7.html)
CA (1) CA2781660C (cg-RX-API-DMAC7.html)
CL (1) CL2012001328A1 (cg-RX-API-DMAC7.html)
CO (1) CO6541645A2 (cg-RX-API-DMAC7.html)
CY (1) CY1117559T1 (cg-RX-API-DMAC7.html)
DK (1) DK2505586T3 (cg-RX-API-DMAC7.html)
ES (1) ES2572935T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160579T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028016T2 (cg-RX-API-DMAC7.html)
IL (1) IL220009A (cg-RX-API-DMAC7.html)
ME (1) ME02447B (cg-RX-API-DMAC7.html)
MX (1) MX2012006017A (cg-RX-API-DMAC7.html)
MY (1) MY161095A (cg-RX-API-DMAC7.html)
NZ (1) NZ600840A (cg-RX-API-DMAC7.html)
PE (1) PE20121358A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501021A1 (cg-RX-API-DMAC7.html)
PL (1) PL2505586T3 (cg-RX-API-DMAC7.html)
PT (1) PT2505586E (cg-RX-API-DMAC7.html)
RS (1) RS54910B1 (cg-RX-API-DMAC7.html)
RU (1) RU2556216C2 (cg-RX-API-DMAC7.html)
SI (1) SI2505586T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600258B (cg-RX-API-DMAC7.html)
TW (1) TWI491591B (cg-RX-API-DMAC7.html)
WO (1) WO2011065402A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼcガンマ2及び耐性に関連した変異
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
ES2748324T3 (es) * 2014-07-04 2020-03-16 Japan Tobacco Inc Método para producir un compuesto de indol
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
CN112118843B (zh) * 2018-05-25 2023-09-29 日本烟草产业株式会社 使用吲哚化合物治疗疼痛或间质性膀胱炎的方法
JP7322007B2 (ja) * 2018-05-25 2023-08-07 日本たばこ産業株式会社 インドール化合物を含むネフローゼ症候群の治療又は予防剤
JP7407705B2 (ja) * 2018-05-25 2024-01-04 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
IL293831B2 (en) 2019-12-20 2024-02-01 Pfizer Benzimidazole derivatives
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
US20240132477A1 (en) * 2020-12-15 2024-04-25 Pfizer Inc. Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease
US20240124439A1 (en) * 2020-12-15 2024-04-18 Pfizer Inc. Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease
US20240279202A1 (en) * 2021-05-03 2024-08-22 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
CA3217892A1 (en) * 2021-05-03 2022-11-10 Joel Mcintosh Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
AU2022370351A1 (en) * 2021-10-19 2024-05-02 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
KR20250166329A (ko) * 2023-04-13 2025-11-27 다나틀라스 파마슈티컬즈 씨오., 엘티디. 티아디아졸론 유도체 및 이의 조성물과 응용

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
BR0213562A (pt) * 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
DK1474425T3 (da) * 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005026175A1 (en) * 2003-09-08 2005-03-24 Aventis Pharmaceuticals Inc. Thienopyrazoles
EP1880993A4 (en) * 2005-04-19 2009-12-30 Kyowa Hakko Kirin Co Ltd NITROGENIC HETEROCYCLIC COMPOUND
EP1968580A2 (en) 2005-12-20 2008-09-17 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
CA2781660C (en) 2018-06-26
PE20121358A1 (es) 2012-10-23
ME02447B (me) 2016-09-20
US20130116240A1 (en) 2013-05-09
ES2572935T3 (es) 2016-06-03
JP2021091718A (ja) 2021-06-17
CN102712624A (zh) 2012-10-03
IL220009A0 (en) 2012-07-31
CO6541645A2 (es) 2012-10-16
NZ600840A (en) 2014-01-31
HUE028016T2 (en) 2016-11-28
SMT201600258B (it) 2016-08-31
TW201124378A (en) 2011-07-16
JP2015172051A (ja) 2015-10-01
CY1117559T1 (el) 2017-04-26
US20180362506A1 (en) 2018-12-20
JP5734628B2 (ja) 2015-06-17
AU2010323579C1 (en) 2016-11-03
DK2505586T3 (en) 2016-05-30
PH12012501021A1 (en) 2013-01-14
CA2781660A1 (en) 2011-06-03
JP2017039761A (ja) 2017-02-23
KR101766502B1 (ko) 2017-08-08
EP3059234A1 (en) 2016-08-24
CL2012001328A1 (es) 2012-10-05
BR112012012529B1 (pt) 2021-10-26
RS54910B1 (sr) 2016-10-31
EP3766877A1 (en) 2021-01-20
MY161095A (en) 2017-04-14
RU2556216C2 (ru) 2015-07-10
KR20120096540A (ko) 2012-08-30
MX2012006017A (es) 2012-06-25
JP2011132222A (ja) 2011-07-07
AU2010323579A1 (en) 2012-07-19
PT2505586E (pt) 2016-06-03
BR112012012529A2 (pt) 2016-05-03
EP2505586A4 (en) 2013-05-15
JP2018158935A (ja) 2018-10-11
PL2505586T3 (pl) 2016-12-30
EP2505586A1 (en) 2012-10-03
TWI491591B (zh) 2015-07-11
US20170267662A1 (en) 2017-09-21
US20110306599A1 (en) 2011-12-15
AU2010323579B2 (en) 2016-05-19
HRP20160579T1 (hr) 2016-07-29
EP2505586B1 (en) 2016-03-02
SI2505586T1 (sl) 2016-08-31
CN102712624B (zh) 2014-06-04
US8299070B2 (en) 2012-10-30
US20210284627A1 (en) 2021-09-16
HK1174025A1 (en) 2013-05-31
WO2011065402A1 (ja) 2011-06-03
RU2012126129A (ru) 2013-12-27
JP2020079276A (ja) 2020-05-28
US20200255408A1 (en) 2020-08-13
IL220009A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
AR079164A1 (es) Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
PE20190446A1 (es) Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4
PE20240687A1 (es) Compuestos de indazol como inhibidores de cinasas
AR070558A1 (es) Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas.
AR099367A1 (es) Inhibidores de la tirosina quinasa de bruton
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
AR110498A1 (es) DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
CL2017000992A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasa
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
AR062680A1 (es) Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
ES2531274T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
PE20160501A1 (es) Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih
ECSP11011200A (es) Derivados de oxadiazale como agonista de los receptores s1p1
AR101986A1 (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
AR076235A1 (es) Compuestos organicos y sus usos
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR092288A1 (es) Ligandos del receptor ep1

Legal Events

Date Code Title Description
FG Grant, registration